6.97
Lifecore Biomedical Inc stock is traded at $6.97, with a volume of 135.54K.
It is up +1.16% in the last 24 hours and up +11.88% over the past month.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
See More
Previous Close:
$6.89
Open:
$6.93
24h Volume:
135.54K
Relative Volume:
0.62
Market Cap:
$269.91M
Revenue:
$128.45M
Net Income/Loss:
$6.54M
P/E Ratio:
139.40
EPS:
0.05
Net Cash Flow:
$-8.79M
1W Performance:
-4.39%
1M Performance:
+11.88%
6M Performance:
+3.41%
1Y Performance:
+6.09%
Lifecore Biomedical Inc Stock (LFCR) Company Profile
Name
Lifecore Biomedical Inc
Sector
Phone
(952) 368-4300
Address
3515 LYMAN BOULEVARD, CHASKA
Compare LFCR with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
LFCR
Lifecore Biomedical Inc
|
6.97 | 269.91M | 128.45M | 6.54M | -8.79M | 0.05 |
![]()
ZTS
Zoetis Inc
|
159.27 | 70.23B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
HLN
Haleon Plc Adr
|
10.74 | 48.23B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.36 | 48.22B | 30.25B | 1.37B | 5.08B | 0.4257 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.93 | 18.57B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
301.42 | 13.29B | 2.76B | 1.11B | 898.10M | 22.77 |
Lifecore Biomedical Inc Stock (LFCR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-05-24 | Initiated | Craig Hallum | Buy |
Aug-28-24 | Downgrade | Barrington Research | Outperform → Mkt Perform |
Mar-20-23 | Downgrade | Stephens | Overweight → Equal-Weight |
Lifecore Biomedical Inc Stock (LFCR) Latest News
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) hedge funds shareholders had a great week as one-year returns increased after a 11% gain last week - Yahoo Finance
A Piece Of The Puzzle Missing From Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) Share Price - simplywall.st
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Raises Stock Holdings in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
When the Price of (LFCR) Talks, People Listen - news.stocktradersdaily.com
Lifecore Biomedical to Participate at Upcoming CDMO Live 2025 Conference - The Manila Times
Quality Management Expert from Lifecore to Chair Strategic Discussion at Major CDMO Conference - Stock Titan
Lifecore Biomedical, Inc. (LFCR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - markets.businessinsider.com
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Lifecore Appoints Top Legal Executive: Stock Price Targets Set at 5x Current Value - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lifecore Biomedical, Inc. (LFCR) and Encourages Stockholders to Learn More About the Investigation - markets.businessinsider.com
Lifecore Biomedical Taps Thomas Salus as Chief Legal & Administration Officer - Contract Pharma
Lifecore Biomedical Appoints Thomas D. Salus as Chief Legal and Administration Officer - GlobeNewswire
Lifecore Strengthens Leadership: Former Viatris Legal Chief Joins to Drive Strategic Growth - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages Lifecore Biomedical, Inc. (LFCR) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Prudential Financial Inc. Makes New $95,000 Investment in Lifecore Biomedical, Inc. (NASDAQ:LFCR) - Defense World
Lifecore Biomedical secures stockholder nod for share issuance - Investing.com Australia
Lifecore Biomedical secures stockholder nod for share issuance By Investing.com - Investing.com South Africa
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Investors to Reach Out - markets.businessinsider.com
LFCR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Lifecore Biomedical, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Lifecore Biomedical, Inc. Under Investigation: Schall Law Firm Encourages Investors with Losses to Reach Out - ACCESS Newswire
Hedge funds owners may consider drastic measures as Lifecore Biomedical, Inc.'s (NASDAQ:LFCR) recent US$65m drop adds to long-term losses - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lifecore Biomedical, Inc. (LFCR) And Encourages Stockholders to Connect - markets.businessinsider.com
(LFCR) Investment Analysis - news.stocktradersdaily.com
Lifecore Biomedical’s Earnings Call: Strategic Optimism Amid Challenges - MSN
Lifecore Biomedical Third Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Lifecore Biomedical, Inc. (NASDAQ:LFCR) Q3 2025 Earnings Call Transcript - Insider Monkey
Sector Update: Health Care Stocks Fall Late Afternoon - MarketScreener
Top Midday Decliners - MarketScreener
Lifecore Biomedical earnings missed by $0.33, revenue topped estimates - Investing.com Canada
Lifecore Biomedical Inc (LFCR) Q3 2025 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Lifecore Biomedical, Inc. (LFCR) And Encourages Shareholders to Reach Out - ACCESS Newswire
Lifecore Biomedical Reports Q3 Fiscal 2025 Results - TipRanks
Lifecore Biomedical (LFCR) Maintains Outlook Amid Strategic Grow - GuruFocus
Lifecore Biomedical targets 12% revenue CAGR and expanded CDMO pipeline by 2027 - MSN
Lifecore Biomedical: Fiscal Q3 Earnings Snapshot - MySA
Lifecore Biomedical (LFCR) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Lifecore Biomedical Reports Third Quarter Fiscal 2025 Financial Results - MarketScreener
Lifecore Biomedical Inc reports results for the quarter ended February 28Earnings Summary - TradingView
Lifecore Biomedical Inc Stock (LFCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):